• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative

    Simply Wall St·10/10/2026 23:25:06
    语音播报

    Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi, backed by a US$1b upfront payment.

    All of this is landing while Regeneron Pharmaceuticals trades at US$746.54, with the share price up over the past quarter but down over the year to date. The 1 year total shareholder return of 32.9% indicates that momentum may be building again as investors reassess the pipeline and risk profile.

    See how Regeneron Pharmaceuticals compares with other late-stage healthcare opportunities by reviewing the hand picked 34 healthcare AI stocks that could be setting up for the next leg higher.

    After a sharp swing over the past year and a US$1b cash injection from Sanofi, Regeneron Pharmaceuticals now sits at a crossroads. Is most of the rerating already in the rear-view mirror, or is meaningful upside still ahead as the pipeline matures and cash flows evolve?

    Most Popular Narrative: 12% Undervalued

    At a last close of $746.54 versus a widely followed fair value of $850.88, the current Regeneron Pharmaceuticals price sits below what that narrative implies. This puts more weight on the drug portfolio than the recent share price suggests.

    Regeneron Pharmaceuticals is still advancing a broad late stage pipeline in areas such as immunology, oncology, genetic medicines, and obesity. Continued readouts and regulatory decisions on these programs can add new revenue streams that support earnings growth beyond the current product portfolio.

    See why 86 investors see Regeneron Pharmaceuticals as 12% undervalued.

    Based on that framework, the narrative applies a 7.55% discount rate and assumes Regeneron Pharmaceuticals can convert a larger late stage pipeline, an expanded Sanofi alliance and potential obesity exposure into higher long term earnings power than the current share price implies. It still acknowledges risks around EYLEA competition, litigation and execution on Dupixent. The result is a fair value estimate of $850.88, which sits above both the $746.54 market level and the analysts' $850.88 consensus target that is grounded in revenue growth of 9.7% a year, a profit margin assumption of 31.9% and a future P/E of 14.9x on projected 2029 earnings of $6.5b.

    Result: Fair Value of $850.88 (UNDERVALUED)

    Still, Kodiak Sciences' Zenkuda challenge in retinal disease and ongoing Libtayo and fianlimab litigation could quickly weaken the current Regeneron Pharmaceuticals undervaluation story.

    Find out about the key risks to this Regeneron Pharmaceuticals narrative.

    Next Steps

    If this Regeneron Pharmaceuticals story feels optimistic to you, you are not alone, although sentiment can reverse quickly so check the underlying numbers yourself. To see what others are focusing on, review the 3 key rewards

    Looking for more investment ideas beyond Regeneron Pharmaceuticals?

    Consider exploring additional opportunities, since the broader market offers a range of different risk and reward profiles that can complement a Regeneron Pharmaceuticals position.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.